Dog-rose, Cranberry leaves, Cranberry Berries, Alfalfa, Fenugreek, Lemon Beebrush, Urtica and Sumac in diabetes mellitus

The Joint Effects of Dog-rose, Cranberry leaves, Cranberry Berries, Alfalfa, Fenugreek, Lemon Beebrush, Urtica, and Sumac for controlling blood glucose of patients with type II diabetes mellitus: A Phase 1-2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220614055167N1

Enrollment

Registered

2023-01-19

Start date

2023-02-28

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus type 2. Type 2 diabetes mellitus

Interventions

Intervention 1: Intervention group: Capsules containing dog-rose, Cranberry leaves, Cranberry Berries, Alfalfa, Fenugreek, Lemon Beebrush, Urtica, and Sumac. Intervention 2: Control group: Placebo cap

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: At least one year of diagnosis of type 2 diabetes according to the criteria of the World Health Organization Hemoglobin A1c (HbA1c)?>?7.0% or fasting blood glucose >?7.0 mmol/L, Body mass index (BMI) more than 23 kg/m2 and less than 35.

Exclusion criteria

Exclusion criteria: Comorbidities, including type 1 diabetes, cardiovascular disease, thyroid disease, kidney disease, cancer, mental disorders, and the use of drugs related to the aforementioned diseases Pregnancy Patients with a BMI over 35 who were on a weight loss diet or had taken weight loss supplements for less than 6 months A history of allergy to one of the components of the nestling fruit, carob leaf, carob fruit, alfalfa seed, fenugreek seed, lemon, Nettles, and sumac Lactating women Regularly consuming cigarettes or alcohol Using psychiatric drugs or insulin Changing the medication regimen during the trial period. For example, to start receiving insulin therapy, become pregnant, or no longer follow medication and dietary instructions

Design outcomes

Primary

Measure	Time frame
Fasting blood glucose. Timepoint: Day 0, 15, 90, 180 post intervention. Method of measurement: Glucometer.	—

Secondary

Measure	Time frame
Insulin level. Timepoint: Day 0, 15, 90, 180 post intervention. Method of measurement: Human Insulin ELISA Test Kit.;Hemoglobin A1c level. Timepoint: Day 0, 15, 90, 180 post intervention. Method of measurement: HbA1c Reagent Kit.;High density lipoprotein (HDL) levels. Timepoint: Day 0, 15, 90, 180 post intervention. Method of measurement: Laboratory kits.;Low density lipoprotein (LDL) levels. Timepoint: Day 0, 15, 90, 180 post intervention. Method of measurement: Laboratory kits.;Triglyceride level. Timepoint: Day 0, 15, 90, 180 post intervention. Method of measurement: Laboratory kits.;Total cholesterol levels. Timepoint: Day 0, 15, 90, 180 post intervention. Method of measurement: Laboratory kits.;Aspartate transaminase level. Timepoint: Day 0, 15, 90, 180 post intervention. Method of measurement: Laboratory kits.;Alanine aminotransferase level. Timepoint: Day 0, 15, 90, 180 post intervention. Method of measurement: Laboratory kits.;Blood urea nitrogen level. Timepoint: Day 0, 15, 90, 180 post intervention. Method of measurement: Laboratory kits.;Creatinine level. Timepoint: Day 0, 15, 90, 180 post intervention. Method of measurement: Laboratory kits.;Prothrombin time. Timepoint: Day 0, 15, 90, 180 post intervention. Method of measurement: Laboratory kits.;Bilirubin level. Timepoint: Day 0, 15, 90, 180 post intervention. Method of measurement: Laboratory kits.;Ferritin level. Timepoint: Day 0, 15, 90, 180 post intervention. Method of measurement: Laboratory kits.;Cholinesterase level. Timepoint: Day 0, 15, 90, 180 post intervention. Method of measurement: Laboratory kits.;High-sensitivity C-reactive protein level. Timepoint: Day 0, 15, 90, 180 post intervention. Method of measurement: Laboratory kits.	—

Measure

Time frame

Insulin level. Timepoint: Day 0, 15, 90, 180 post intervention. Method of measurement: Human Insulin ELISA Test Kit.;Hemoglobin A1c level. Timepoint: Day 0, 15, 90, 180 post intervention. Method of measurement: HbA1c Reagent Kit.;High density lipoprotein (HDL) levels. Timepoint: Day 0, 15, 90, 180 post intervention. Method of measurement: Laboratory kits.;Low density lipoprotein (LDL) levels. Timepoint: Day 0, 15, 90, 180 post intervention. Method of measurement: Laboratory kits.;Triglyceride level. Timepoint: Day 0, 15, 90, 180 post intervention. Method of measurement: Laboratory kits.;Total cholesterol levels. Timepoint: Day 0, 15, 90, 180 post intervention. Method of measurement: Laboratory kits.;Aspartate transaminase level. Timepoint: Day 0, 15, 90, 180 post intervention. Method of measurement: Laboratory kits.;Alanine aminotransferase level. Timepoint: Day 0, 15, 90, 180 post intervention. Method of measurement: Laboratory kits.;Blood urea nitrogen level. Timepoint: Day 0, 15, 90, 180 post intervention. Method of measurement: Laboratory kits.;Creatinine level. Timepoint: Day 0, 15, 90, 180 post intervention. Method of measurement: Laboratory kits.;Prothrombin time. Timepoint: Day 0, 15, 90, 180 post intervention. Method of measurement: Laboratory kits.;Bilirubin level. Timepoint: Day 0, 15, 90, 180 post intervention. Method of measurement: Laboratory kits.;Ferritin level. Timepoint: Day 0, 15, 90, 180 post intervention. Method of measurement: Laboratory kits.;Cholinesterase level. Timepoint: Day 0, 15, 90, 180 post intervention. Method of measurement: Laboratory kits.;High-sensitivity C-reactive protein level. Timepoint: Day 0, 15, 90, 180 post intervention. Method of measurement: Laboratory kits.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaeid Safiri

Tabriz University of Medical Sciences

saeidsafiri@gmail.com+98 41 3334 7882

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026